Your cart is empty
Start Shopping$68.00
When used together, CJC-1295 and Ipamorelin are believed to synergize to create a more powerful and comprehensive effect on GH release. This is because they act on different receptor pathways in the pituitary gland, resulting in a dual-action approach. CJC-1295 provides a sustained, elevated background of GH, while Ipamorelin provides a strong, pulsatile boost that mimics the body's natural GH release. This combination is theorized to maximize the overall therapeutic benefits and leads to more pronounced results than using either peptide alone.
This material is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.
Research Summary | Description |
---|---|
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse |
Summary: This study demonstrated that once-daily administration of CJC-1295 (without DAC) was able to normalize body weight and length in GHRH knockout mice. This effect was accompanied by an increase in total pituitary RNA and GH mRNA, suggesting somatotroph cell proliferation. Citation: Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J. P., Frohman, L. A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290-E1294. |
What is CJC1295 without DAC? |
Summary: This article highlights that CJC1295 without DAC has a relatively short half-life, typically around 30 minutes to an hour. This contrasts sharply with the DAC-modified version, which can have a half-life of 6 to 8 days due to its binding to albumin. Citation: Bocsci. (n.d.). What is CJC1295 without DAC? |
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog |
Summary: This study, which introduced CJC-1295 (the DAC version), noted that the first 29 amino acids of GHRH (sermorelin) were as potent as the full 44-amino acid structure, but had rapid metabolic clearance. This led to the development of analogues like Modified GRF (1-29) to enhance biological activity and reduce rapid metabolic clearance. Citation: Jetté, L., Léger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Pellerin, I.,... & Abribat, T. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 146(7), 3052-3058. |
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. |
Summary: While this study primarily focuses on CJC-1295 with DAC, it is foundational to understanding the broader family of GHRH analogs, including the principles behind CJC-1295 no DAC. This randomized, placebo-controlled, double-blind study in healthy adults (ages 21-61) demonstrated that subcutaneous administration of CJC-1295 (DAC) led to sustained, dose-dependent increases in mean plasma GH concentrations (2- to 10-fold for 6 days or more) and IGF-I concentrations (1.5- to 3-fold for 9-11 days). The estimated half-life of CJC-1295 (DAC) was 5.8-8.1 days. It was found to be safe and relatively well tolerated. This study implies the potential for GHRH analogs to impact GH and IGF-I levels. Citation: Teichman, S. L., Neale, A., Lawrence, B., Gagnon, R., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536 |
Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats |
Summary: This study demonstrated that Ipamorelin dose-dependently increased the longitudinal bone growth rate (LGR) and body weight gain in adult female rats. Citation: Johansen, P. B., Nowak, J., Skjaerbaek, C., Flyvbjerg, A., Andreassen, T. T., Wilken, M., & Orskov, H. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research, 9(2), 106-113. |
Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus |
Summary: This study showed that Ipamorelin accelerated gastric emptying and intestinal transit in a rodent model of postoperative ileus (POI). This effect is mediated by its action on ghrelin receptors located on cholinergic neurons in the gut. Citation: Beck, D. E., Sweeney, W. B., & McCarter, M. D. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527-1534. |
Ipamorelin, the first selective growth hormone secretagogue |
Summary: This study identified Ipamorelin as the first selective growth hormone secretagogue. This selectivity means it stimulates GH release without significantly affecting other hormones like adrenocorticotropic hormone (ACTH) and cortisol, unlike some other GH-releasing peptides. Citation: Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561. |
The benefits of Ipamorelin growth hormone |
Summary: This article states that Ipamorelin increases growth hormone levels by stimulating the hypothalamus, leading to increased muscle mass and strength, as well as fat loss due to increased metabolism and lipolysis. It also notes benefits such as improved workouts and recovery, reduced body fat, increased energy, and deeper sleep. Citation: NYMD Center. (n.d.). The Benefits of Ipamorelin Growth Hormone. |
Summary: This study demonstrated that once-daily administration of CJC-1295 (without DAC) was able to normalize body weight and length in GHRH knockout mice. This effect was accompanied by an increase in total pituitary RNA and GH mRNA, suggesting somatotroph cell proliferation.
Citation: Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J. P., Frohman, L. A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290-E1294.
Summary: This article highlights that CJC1295 without DAC has a relatively short half-life, typically around 30 minutes to an hour. This contrasts sharply with the DAC-modified version, which can have a half-life of 6 to 8 days due to its binding to albumin.
Citation: Bocsci. (n.d.). What is CJC1295 without DAC?
Summary: This study, which introduced CJC-1295 (the DAC version), noted that the first 29 amino acids of GHRH (sermorelin) were as potent as the full 44-amino acid structure, but had rapid metabolic clearance. This led to the development of analogues like Modified GRF (1-29) to enhance biological activity and reduce rapid metabolic clearance.
Citation: Jetté, L., Léger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Pellerin, I.,... & Abribat, T. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 146(7), 3052-3058.
Summary: While this study primarily focuses on CJC-1295 with DAC, it is foundational to understanding the broader family of GHRH analogs, including the principles behind CJC-1295 no DAC. This randomized, placebo-controlled, double-blind study in healthy adults (ages 21-61) demonstrated that subcutaneous administration of CJC-1295 (DAC) led to sustained, dose-dependent increases in mean plasma GH concentrations (2- to 10-fold for 6 days or more) and IGF-I concentrations (1.5- to 3-fold for 9-11 days). The estimated half-life of CJC-1295 (DAC) was 5.8-8.1 days. It was found to be safe and relatively well tolerated. This study implies the potential for GHRH analogs to impact GH and IGF-I levels.
Citation:
Teichman, S. L., Neale, A., Lawrence, B., Gagnon, R., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
Summary: This study demonstrated that Ipamorelin dose-dependently increased the longitudinal bone growth rate (LGR) and body weight gain in adult female rats.
Citation: Johansen, P. B., Nowak, J., Skjaerbaek, C., Flyvbjerg, A., Andreassen, T. T., Wilken, M., & Orskov, H. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research, 9(2), 106-113.
Summary: This study showed that Ipamorelin accelerated gastric emptying and intestinal transit in a rodent model of postoperative ileus (POI). This effect is mediated by its action on ghrelin receptors located on cholinergic neurons in the gut.
Citation: Beck, D. E., Sweeney, W. B., & McCarter, M. D. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527-1534.
Summary: This study identified Ipamorelin as the first selective growth hormone secretagogue. This selectivity means it stimulates GH release without significantly affecting other hormones like adrenocorticotropic hormone (ACTH) and cortisol, unlike some other GH-releasing peptides.
Citation: Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561.
Summary: This article states that Ipamorelin increases growth hormone levels by stimulating the hypothalamus, leading to increased muscle mass and strength, as well as fat loss due to increased metabolism and lipolysis. It also notes benefits such as improved workouts and recovery, reduced body fat, increased energy, and deeper sleep.
Citation: NYMD Center. (n.d.). The Benefits of Ipamorelin Growth Hormone.
Your cart is empty
Start Shopping